These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31406978)

  • 41. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
    Mailman RB; Murthy V
    Curr Pharm Des; 2010; 16(5):488-501. PubMed ID: 19909227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
    Centorrino F; Fogarty KV; Cimbolli P; Salvatore P; Thompson TA; Sani G; Cincotta SL; Baldessarini RJ
    J Psychiatr Pract; 2005 Jul; 11(4):241-7. PubMed ID: 16041234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review of the safety and tolerability of aripiprazole.
    Pae CU
    Expert Opin Drug Saf; 2009 May; 8(3):373-86. PubMed ID: 19505266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
    Yasui-Furukori N; Kaneda A; Sugawara N; Tomita T; Kaneko S
    J Psychopharmacol; 2012 Jun; 26(6):806-12. PubMed ID: 21616975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
    Lobo MC; Whitehurst TS; Kaar SJ; Howes OD
    Neurosci Biobehav Rev; 2022 Jan; 132():324-361. PubMed ID: 34838528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the dopamine D2 receptor in schizophrenia.
    Seeman P
    Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
    Misiak B; Bieńkowski P; Samochowiec J
    Psychiatr Pol; 2018 Dec; 52(6):971-981. PubMed ID: 30659560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders.
    Wichniak A; Samochowiec J; Szulc A; Dudek D; Heitzman J; Janas-Kozik M; Wolańczyk T; Rymaszewska J; Siwek M; Bieńkowski P
    Psychiatr Pol; 2021 Oct; 55(5):941-966. PubMed ID: 34997736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
    Bruijnzeel D; Tandon R
    Drug Des Devel Ther; 2016; 10():1641-7. PubMed ID: 27274197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
    Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
    Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brexpiprazole for treatment-resistant major depressive disorder.
    Fornaro M; Fusco A; Anastasia A; Cattaneo CI; De Berardis D
    Expert Opin Pharmacother; 2019 Nov; 20(16):1925-1933. PubMed ID: 31431092
    [No Abstract]   [Full Text] [Related]  

  • 54. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
    Wood M; Reavill C
    Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 Feb; 57(2):7-11. PubMed ID: 30703220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    Kessler RM
    Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
    [No Abstract]   [Full Text] [Related]  

  • 60. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.